Key takeaways
- DSIP is the nine-amino-acid peptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; emideltide is its international nonproprietary name.
- Its name comes from 1977 rabbit studies that measured delta waves on the EEG; a 2006 review called the idea of DSIP as a sleep factor “extremely poorly documented and still weak”.
- The human studies FDA staff describe were small, published between 1981 and 1998, and FDA staff called the insomnia evidence “inconclusive and at best preliminary”.
- FDA staff recommended against adding it to the 503A bulks list; by press reports, the July 2026 advisory committee voted 7 to 6 against, with one abstention.
- It is not FDA-approved, is not in HHS’s October 2026 compounding policy, and is not named on WADA’s 2026 or 2027 List.
01DSIP at a glance
The short version, dated 18 November 2026. Every line is sourced at the end of the page.
| Question | DSIP (emideltide) |
|---|---|
| What it is | A peptide of nine amino acids, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (C35H48N10O15, 848.8 g/mol), characterised from rabbits in 1977. |
| Other names | Delta sleep-inducing peptide; emideltide, its international nonproprietary name (INN). |
| Evidence tier | T3 for the EEG findings in rabbits, rats and cats. T2 for people: the placebo-controlled studies FDA staff describe in detail had 6 to 16 people each. |
| Human studies | 209 people, for 1 to 15 days each, in the studies FDA staff found, from 1981 on. None on ClinicalTrials.gov (searched 18 Nov 2026). |
| United States | Not FDA-approved. Formerly in compounding Category 2; both nominations withdrawn in April 2026 (FDA docket, posted 14 Apr 2026; FDA list, current 22 Apr 2026). FDA staff recommended against the 503A bulks list; by press reports, the July 2026 committee voted 7 to 6 against. Not in HHS’s October 2026 policy. |
| United Kingdom and Europe | No result on the UK emc database (18 Nov 2026); not a registered drug in any country FDA staff searched. |
| Australia | Not named in the Poisons Standard October 2026 (text searched 18 Nov 2026). |
| WADA | Not named on the 2026 or 2027 List; check with your anti-doping body. |
02What is DSIP, and where does its name come from?
DSIP is a short peptide of nine amino acids. In 1977, researchers in Basel described it from rabbits and reported that, infused into the brain, it increased delta waves and spindles on the EEG, the electrical patterns of deep non-REM sleep, in a study of 58 rabbits including controls. The name comes from that finding (T3). It is not a result in people.
Later animal work did not settle it. FDA staff summarise rabbit, rat and cat studies that recorded more delta activity or longer non-REM sleep, and describe the effect in animals as “conserved across species” (T3). They also note inconsistent findings: a 1980 rat study found no increase in delta waves, and cat and rat studies disagree on which sleep stages change. A 2006 review was more sceptical: the link between DSIP and sleep “has never been further characterized”, partly because no DSIP gene, precursor protein or receptor had been isolated, and the idea of DSIP as a sleep factor is “extremely poorly documented and still weak”.
In rats, a drug that blocks opioid receptors prevented DSIP’s effect on sleep, although DSIP does not bind those receptors itself, FDA staff write: its effects appear to run partly through the opioid system.
FDA staff also found different salts and derivatives sold under the same name, and concluded that neither emideltide nor its acetate salt is “well-characterized”.
03How has DSIP been studied in people, and what did FDA staff conclude?
Small studies, most from the 1980s, reviewed by FDA staff in 2026 for three uses nominators proposed: chronic insomnia, narcolepsy and opioid withdrawal.
| Study | People | Design | What the authors or FDA staff concluded |
|---|---|---|---|
| Schneider-Helmert et al., 1981 | 6 healthy volunteers | Double-blind, placebo-controlled crossover | FDA staff: the first-in-human pilot; sleep recordings and ratings |
| Schneider-Helmert and Schoenenberger, 1981 | 6 adults with chronic insomnia | Randomised, double-blind, placebo-controlled crossover | FDA staff: results given mostly as p values, and unclear whether changes were clinically meaningful |
| Schneider-Helmert, 1987 | 14 adults with chronic insomnia | Double-blind; compared with healthy external controls, with no placebo arm | FDA staff: small sample and poor methodology limit interpretation |
| Monti et al., 1987 | 6 adults with severe chronic insomnia | Randomised, double-blind, placebo-controlled crossover | FDA staff: no significant differences from baseline or placebo; the authors judged the changes “of little clinical significance” |
| Bes et al., 1992 | 16 adults with chronic insomnia | Double-blind, placebo-controlled, two parallel groups | The authors: effects were weak and “not likely to be of major therapeutic benefit” |
| Dick et al., 1984; Backmund et al., 1998 | 107 people in alcohol or opioid withdrawal; 7 in opioid withdrawal | Open-label, no comparison group | FDA staff: small, unblinded and uncontrolled |
| Schneider-Helmert, 1984 | 1 man with narcolepsy | Case report | FDA staff: a single case limits interpretation |
FDA staff’s verdict: studies authored by Schneider-Helmert reported improved sleep measures, while the two double-blind, placebo-controlled studies from other groups “did not reach the same conclusions”. They called the insomnia evidence “inconclusive and at best preliminary”, found insufficient evidence for all three uses, and found no study of the route the nominators proposed and no information on benefit with long-term use.
04What have regulators said about DSIP safety?
FDA staff found no safety data for the route nominators proposed and called DSIP’s safety “insufficiently characterized”. Both sides of their review:
What was reported. FAERS, FDA’s adverse-event database, held no reports for emideltide through 3 March 2024, and FDA staff found no published case reports. The insomnia studies reported no significant adverse effects. In a 1984 withdrawal study of 107 people, nine had minor, short-lived effects such as headache, nausea and vertigo, and three had serious adverse effects: two had a fall in blood pressure as treatment began, and one had repeated discomfort with sweating and nausea. One of these three, given it a second time, had “progressive hypotension”. FDA staff note that withdrawal symptoms make these reports hard to interpret.
What FDA staff found missing. FDA staff found no toxicity studies of repeated exposure, no reproductive studies and no two-year cancer studies in animals. A mouse study of Deltaran, a Russian product combining DSIP with glycine, cannot show that DSIP lacks cancer or genetic-damage potential, they wrote, partly because glycine, the other ingredient, has itself been reported to have anti-mutagenic and anti-cancer properties.
Two concerns. Because DSIP’s effects in animals involve the opioid system, FDA staff wrote that this “could lead to development of addiction”, and they found no study of its abuse potential. And as a nine-amino-acid peptide given by the route nominators proposed, emideltide “may pose a significant risk for immunogenicity”, an unwanted immune response. More: side effects, documented vs unknown.
05Is DSIP an approved medicine? Status by country
United States. DSIP is not an FDA-approved drug or a component of one. FDA’s compounding page lists “Emideltide (DSIP)” among substances previously in Category 2 whose nominations were withdrawn; the page is current as of 22 April 2026, and FDA’s docket posted the two nominators’ withdrawal letters on 14 April 2026. FDA staff, evaluating it on the agency’s own initiative, proposed not adding either form to the 503A bulks list. At the advisory committee meeting of 24 July 2026, by press reports, members voted 7 to 6 against adding emideltide, with one abstention; FDA had posted no minutes by 18 November 2026. DSIP is not among the six peptides in HHS’s October 2026 enforcement-discretion policy. Background: the July 2026 vote, the HHS policy, FDA’s categories.
United Kingdom and Europe. Searches of the emc database for emideltide and for DSIP returned no results on 18 November 2026. FDA staff found no monograph in the European, Japanese or International Pharmacopoeia, and no country among those they searched where emideltide is a registered drug. More: are peptides legal in the UK?
Australia. Emideltide is not named in the Poisons Standard October 2026, and we found no group entry that would cover it. More: are peptides legal in Australia?
Sport. DSIP is not named on WADA’s 2026 or 2027 Prohibited List. Class S0 prohibits at all times any substance not addressed elsewhere on the List “and with no current approval by any governmental regulatory health authority for human therapeutic use”. FDA staff found no country, among those they searched, where emideltide is a registered drug; anti-doping organisations decide how S0 applies. See peptides and anti-doping.
06What we don’t know about DSIP
- Whether DSIP changes sleep in people. The placebo-controlled studies were small, disagreed with each other, and none is recent.
- Whether the body uses DSIP as a sleep signal at all: its gene, precursor and receptor had not been isolated by 2006.
- Its safety with repeated use or by the route nominators proposed, and its abuse potential. FDA staff found these unstudied.
- What a vial sold as DSIP contains. The name is used for different salts and derivatives; only a lab report on that lot can show it: how to read a COA.
Related: the sleep research area and the epitalon guide.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.